Celltech rises on encouraging test results
Wednesday 10 May 1995
Clinical trials for three promising new medical compounds are continuing to go well for Celltech, the biotechnology company, which floated at 250p nearly 18 months ago.
The encouraging progress, combined with news that interim losses have been cut by £300,000 to £4.1m, was well received by the stock market, which marked up Celltech's shares by 2.5p to 307p yesterday.
Peter Fellner, chief executive, said: "The trials are very much on track and there have been no unpleasant surprises as some others in the sector have had." The second phase of studies to determine whether the compounds actually work is now under way, he said.
None of the expected side-effects have shown up in a new oral treatment for mild and moderate asthma, code-named CDP 840, which could be submitted for licensing in 1998. The potential for the drug, being developed with Merck, should be clearer by the end of this year, Mr Fellner said. The market is huge, with $6bn being spent on existing products like Ventolin and Tilade last year.
But, if tests go well, Celltech's first approvals are likely to be for a drug being developed with Bayer to combat inflammatory bowel disorders, called CDP 571, and an anti-leukaemia compound that American Home Products is backing, entitled CDP 771. Mr Fellner said filings could come as early as 1997.
Celltech differentiates itself from other recent biotechnology offerings by its higher levels of external income. Turnover from its business making antibodies for groups like Roche and Johnson & Johnson rose from £6.5m to £7.2m in the six months to March. With interest income - £900,000 in the half-year, down from £1m before - that is meant to fund half the research and development budget, with the rest coming from big drug company partners. Mr Fellner was pleased with the fall in half-year losses, despite having raised R&D spending by £1m to £8.8m last year.
- 1 Man on naked bike ride gets ejected after becoming aroused
- 2 Charles Kennedy 1959-2015: A gifted, compassionate politician whose career was cut short by the 'demon drink' - latest news
- 3 Ann Summers survey reveals the UK's favourite sex position
- 4 Jaden Smith wears gender fluid dress to high school prom with Hunger Games actress
- 5 How much sex should I be having?
Ed Miliband returns to the backbenches but it's all a bit awkward as he tries to avoid eye-contact with fellow Labour MPs
Man on naked bike ride gets ejected after becoming aroused
Charles Kennedy 1959-2015: A gifted, compassionate politician whose career was cut short by the 'demon drink' - latest news
Ayyan Ali: Pakistan's top model now appears in the courtroom rather than on the catwalk
Isis tortures 14-year-old Syrian boy and films it in graphic video for 'propaganda purposes'
Migrants in Kos: Photos show real tragedy after Brits abroad complain of 'awkward' holidays
Thousands of teenage girls enduring debilitating illnesses after routine school cancer vaccination
British tourists complain that impoverished boat migrants are making holidays 'awkward' in Kos
Michael Gove determined to scrap the Human Rights Act – even if Scotland retains it
Threat to scrap Human Rights Act could see UK follow Nazi example, warns UN official
Why this year's general election was the most unfair in Britain's history
iJobs Money & Business
£30000 - £35000 per annum: Recruitment Genius: The UK's fastest growing, multi...
£70000 - £90000 per annum: Recruitment Genius: A Financial Reporting Manager i...
£23000 - £25000 per annum: Recruitment Genius: They win lots of awards for the...
£13500 - £20000 per annum: Recruitment Genius: This nationwide enforcement com...